Novo Nordisk and Eli Lilly pivot to oral obesity drugs as next growth frontier after injectable success
Executive summary: Novo Nordisk and Eli Lilly are accelerating development and preparing international rollout of oral versions of their obesity treatments, following successful U.S. launches of their injectable counterparts. Oral formulations could significantly increase patient access and adherence by eliminating the need for injections, potentially expanding the obesity drug market beyond current injectable users.
Who is involved: Novo Nordisk, Eli Lilly, patients with obesity, healthcare providers, and regulatory agencies overseeing drug approvals.
Likely next: Regulatory submissions for oral obesity drugs in key international markets, followed by phased country launches and potential pricing and reimbursement negotiations.
Pharmaceutical giants Novo Nordisk and Eli Lilly are advancing oral formulations of their blockbuster weight-loss drugs, building on the proven efficacy and market dominance of their injectable versions. After a successful U.S. launch, both companies are preparing for broader international rollout, signaling a strategic shift toward more accessible and patient-friendly delivery methods. This move aims to expand patient adherence and tap into a larger addressable market by overcoming barriers associated with injections. The development underscores intensifying competition in the obesity therapeutics space, where convenience and scalability are becoming key differentiators.
Timeline
- — Les comprimés, nouveau champ de bataille des médicaments contre l’obésité (Le Monde — Économie)
Analysis — what this means
Likely next events
- Novo Nordisk to submit oral semaglutide for EMA review by Q4 2026
- Eli Lilly to present Phase 3 oral tirzepatide data at ADA 2027
- First oral obesity drug approvals expected in EU and Canada by mid-2027
Sectors affected
- Pharmaceuticals (obesity therapeutics)
- Medical devices (injectable pen manufacturers)
- Healthcare insurance and pharmacy benefit managers
Regulatory implications
- EMA and FDA to evaluate long-term safety of oral GLP-1/GIP receptor agonists
- Pricing negotiations likely in EU countries due to budget impact concerns
Historical parallels
- Insulin transition from injectable to inhaled (Exubera, 2006 – withdrawn due to poor uptake)
- Shift from injectable to oral antivirals in HIV treatment (late 1990s)
- Oral semaglutide (Rybelsus) approval for type 2 diabetes in 2019
Sources
- Les comprimés, nouveau champ de bataille des médicaments contre l’obésité — Le Monde — Économie
Related cases
- China’s acceptance of Novo Nordisk’s oral obesity pill application opens a major growth avenue in the world’s second-largest pharma market
- Novo Nordisk partners with AWS to boost AI-driven drug discovery, aiming to speed up development timelines
- Eli Lilly expands its weight‑loss portfolio to cover diverse patient profiles, aiming to capture broader market share
- Fangzhou rolls out Novo Nordisk’s once‑weekly basal insulin/GLP-1 therapy in China, creating a new convenience‑driven option in the diabetes market
- Eli Lilly and Teva face off as investors weigh which pharma stock offers better value in 2026 amid shifting drug pricing and biotech financing trends
- UK private launch of oral Wegovy signals expansion of obesity drug market beyond injectables